Evidence map›Paper›PMID 38501011›Full record

ArticleHeliyon2024

Identification of novel mutations in

Fatemeh Norouzi Rostami, Hossein Sadeghi, Farzad Hashemi-Gorji, Sahand Tehrani Fateh, Reza Mirfakhraie, Parvaneh Karimzadeh, Milad Davarpanah, Sanaz Jamshidi, Rasoul Madannejad, Parinaz Moghimi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Fatemeh Norouzi RostamiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hossein SadeghiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farzad Hashemi-GorjiGenomic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sahand Tehrani FatehSchool of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Reza MirfakhraieDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Parvaneh KarimzadehDepartment of Pediatric Neurology, School of Medicine, Pediatric Neurology Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Milad DavarpanahStudents' Research Committee, Isfahan University of Medical Science, Isfahan, Iran.
Sanaz JamshidiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rasoul MadannejadCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Parinaz MoghimiSchool of Medicine, Islamic Azad University Tehran Medical Sciences, Tehran, Iran.
Mahdis EkramiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad MiryounesiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad-Reza GhasemiCenter for Comprehensive Genetic Services, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahid Beheshti University of Medical Sciences · IRIslamic Azad University Medical Branch of Tehran · IRTehran University of Medical Sciences · IRUniversity of Isfahan · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: The occurrence of thiamine metabolism dysfunction syndrome (THMD), a rare autosomal recessive condition, may be linked to various mutations found in the Material and methods: The selection of cases for this study was based on the phenotypic and genetic information that was obtainable from the Center for Comprehensive Genetic Services. The genetic basis for the problems observed among the participants was determined through the application of whole-exome sequencing (WES). Subsequently, sanger sequencing was employed as a means of validating any identified variations suspected to be causative. Results: The first patient exhibited a homozygous mutation in the Conclusions: Collectively, when presented with patients showcasing ataxia, encephalopathy, and basal ganglia necrosis, it is essential to account for thiamine deficiency in light of the potential advantages of prompt intervention. At times, it may be feasible to rectify this deficiency through the timely administration of thiamine dosages. Accordingly, based on the results of the current investigation, these variations may be useful for the diagnosis and management of patients with THMD.

Indexed as

Novel mutationsSLC19A3Thiamine metabolism dysfunction syndromeTPK1Whole-exome sequencing (WES)

Identifiers

PMID38501011
PMCPMC10945192
OpenAlexW4392514127

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.